Cover Image
市場調查報告書

QUANTUM GENOMICS Corp.的產品平台分析

QUANTUM GENOMICS Corp. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 321954
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
QUANTUM GENOMICS Corp.的產品平台分析 QUANTUM GENOMICS Corp. - Product Pipeline Review - 2014
出版日期: 2014年12月31日 內容資訊: 英文 23 Pages
簡介

QUANTUM GENOMICS Corp.是總公司設立於美國的生物製藥企業。正與各種研究所、學術轉隊、製藥企業及生物科學企業共同開發高血壓和心臟衰竭等心血管系統疾病領域的新治療藥。

本報告提供QUANTUM GENOMICS Corp. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

QUANTUM GENOMICS Corp. 的基本資料

  • QUANTUM GENOMICS Corp. 概要
  • 主要資訊
  • 企業資料

QUANTUM GENOMICS Corp. :R&D概要

  • 主要的治療範圍

QUANTUM GENOMICS Corp. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

QUANTUM GENOMICS Corp. :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

QUANTUM GENOMICS Corp. :藥物簡介

  • QGC-001
  • QGC-011
  • QGC-101
  • QGC-006

QUANTUM GENOMICS Corp. :開發平台分析

  • 各給藥途徑
  • 各分子類型

QUANTUM GENOMICS Corp. :最新的開發平台資訊

QUANTUM GENOMICS Corp. :開發暫停中的計劃

QUANTUM GENOMICS Corp. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06773CDB

Summary

Global Markets Direct's, 'QUANTUM GENOMICS Corp. - Product Pipeline Review - 2014', provides an overview of the QUANTUM GENOMICS Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of QUANTUM GENOMICS Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of QUANTUM GENOMICS Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of QUANTUM GENOMICS Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the QUANTUM GENOMICS Corp.'s pipeline products

Reasons to buy

  • Evaluate QUANTUM GENOMICS Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of QUANTUM GENOMICS Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the QUANTUM GENOMICS Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of QUANTUM GENOMICS Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of QUANTUM GENOMICS Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of QUANTUM GENOMICS Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • QUANTUM GENOMICS Corp. Snapshot
    • QUANTUM GENOMICS Corp. Overview
    • Key Information
    • Key Facts
  • QUANTUM GENOMICS Corp.- Research and Development Overview
    • Key Therapeutic Areas
  • QUANTUM GENOMICS Corp.- Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products- Monotherapy
  • QUANTUM GENOMICS Corp.- Pipeline Products Glance
    • QUANTUM GENOMICS Corp.- Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • QUANTUM GENOMICS Corp.- Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • QUANTUM GENOMICS Corp.- Drug Profiles
    • QGC-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • QGC-011
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • QGC-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • QGC-006
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • QUANTUM GENOMICS Corp.- Pipeline Products by Route of Administration
    • QUANTUM GENOMICS Corp.- Pipeline Products by Molecule Type
  • QUANTUM GENOMICS Corp.- Recent Pipeline Updates
  • QUANTUM GENOMICS Corp.- Dormant Projects
  • QUANTUM GENOMICS Corp.- Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • QUANTUM GENOMICS Corp., Key Information
  • QUANTUM GENOMICS Corp., Key Facts
  • QUANTUM GENOMICS Corp.- Pipeline by Indication, 2014
  • QUANTUM GENOMICS Corp.- Pipeline by Stage of Development, 2014
  • QUANTUM GENOMICS Corp.- Monotherapy Products in Pipeline, 2014
  • QUANTUM GENOMICS Corp.- Phase II, 2014
  • QUANTUM GENOMICS Corp.- Preclinical, 2014
  • QUANTUM GENOMICS Corp.- Discovery, 2014
  • QUANTUM GENOMICS Corp.- Pipeline by Route of Administration, 2014
  • QUANTUM GENOMICS Corp.- Pipeline by Molecule Type, 2014
  • QUANTUM GENOMICS Corp.- Recent Pipeline Updates, 2014
  • QUANTUM GENOMICS Corp.- Dormant Developmental Projects,2014
  • QUANTUM GENOMICS Corp., Subsidiaries

List of Figures

  • QUANTUM GENOMICS Corp. - Pipeline by Top 10 Indication, 2014
  • QUANTUM GENOMICS Corp. - Pipeline by Stage of Development, 2014
  • QUANTUM GENOMICS Corp. - Monotherapy Products in Pipeline, 2014
Back to Top